This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Edwards Lifesciences (EW), Encompass Health (EHC) and Moderna (MRNA)

Tipranks - Tipranks - Sat Jun 27, 6:45AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Edwards Lifesciences (EW), Encompass Health (EHC) and Moderna (MRNA).

TipRanks' Prime Week Sale - 70% Off

Edwards Lifesciences (EW)

TD Cowen analyst Josh Jennings maintained a Buy rating on Edwards Lifesciences today and set a price target of $104.00. The company’s shares closed last Thursday at $89.72.

According to TipRanks.com, Jennings is a 3-star analyst with an average return of 2.3% and a 43.6% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Anteris Technologies Global Corp., Establishment Labs Holdings, and Orchestra BioMed Holdings. ;'>

Edwards Lifesciences has an analyst consensus of Strong Buy, with a price target consensus of $98.40, which is a 9.2% upside from current levels. In a report issued on June 11, RBC Capital also maintained a Buy rating on the stock with a $100.00 price target.

See the top stocks recommended by analysts >>

Encompass Health (EHC)

In a report released today, David S Macdonald from Truist Financial reiterated a Buy rating on Encompass Health, with a price target of $140.00. The company’s shares closed last Thursday at $99.72.

According to TipRanks.com, Macdonald is a 5-star analyst with an average return of 10.9% and a 58.4% success rate. Macdonald covers the Healthcare sector, focusing on stocks such as Guardian Pharmacy Services, Inc. Class A, Concentra Group Holdings Parent, Inc., and Ardent Health Partners, Inc. ;'>

Currently, the analyst consensus on Encompass Health is a Strong Buy with an average price target of $136.25, a 33.5% upside from current levels. In a report issued on June 12, KeyBanc also maintained a Buy rating on the stock.

Moderna (MRNA)

Bernstein analyst Courtney Breen maintained a Hold rating on Moderna yesterday and set a price target of $45.00. The company’s shares closed last Thursday at $59.75.

According to TipRanks.com, Breen is a 4-star analyst with an average return of 16.8% and a 82.7% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Merck & Company, and Gilead Sciences. ;'>

Moderna has an analyst consensus of Hold, with a price target consensus of $44.85, which is a -25.7% downside from current levels. In a report issued on June 16, Jefferies also maintained a Hold rating on the stock with a $45.00 price target.

Read More on EW:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).